Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities remains negative
Q1 FY2026 other non-current liabilities was $0, compared with $0 a year earlier.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 170.78M | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Non-current Liabilities vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 other non-current liabilities of $0 is the 6th highest of the 10 companies compared; the peer median is $1.14M.
- Other non-current liabilities amounts to 0.0% of total assets for RAPP, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $69.14M | -13.2% | +20.5% | 9.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $52.96M | — | -59.9% | 34.4% |
| Sep 2026 | $17.12M | +23.3% | +28.2% | 1.0% | |
| Mar 2026 | $16.22M | — | +114.0% | 5.9% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $1.14M | -40.6% | -62.6% | 0.3% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Sep 2026 | $0 | — | — | 0.0% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $1.14M | -13.2% | +20.5% | 0.3% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.